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Objectives. A cribriform architectural pattern has been reported in 9% of one unselected consecutively collected series of gastric
carcinomas (GC) with unfavourable prognostic outcome. Taking into consideration the biological relevance of the human
epidermal growth factor receptor 2 (HER2) status, we have analyzed a cohort of GC with a cribriform component more than
40% (CGC) to evaluate the HER2 amplification rate as a potential target for therapy with trastuzumab. Results. HER2
overexpression was encountered in 21 of 100 (21%) GC; a progressive increase in HER2 amplification was appreciated moving
from non-CGC (20.6%) towards CGC cases (21.6%), although this difference does not reach a statistical significance.
Nevertheless, either in univariate or in multivariate analyses, stage and HER2 status showed a significant p value (<0.001) in
CGC patients. Conclusions. Our data confirmed a worse prognosis in all CGC patients with HER2 amplification, resulting in a
shorter survival time. We invite all pathologists in their daily practice to specify the occurrence of cribriform neoplastic
component in GC, either in surgical or in bioptical samples, taking into practical assessment the high HER2 overexpression rate
in order to correctly treat these patients with worse behavior.
1. Introduction
The cribriform histological pattern has been attributed to
tumors showing an architecture made of straight packed
glands with not uniform distributed lumina, without inter-
posed stromal tissue [1, 2]. This peculiar pattern has been
identified in invasive carcinomas rising in many different
organs, such as prostate, breast, lung, colon, thyroid, skin,
and stomach [2–7]. In this latter localization, a specific
cribriform gastric carcinoma (CGC) has not been described
in the lastWHO classification of gastrointestinal tract tumors
[8], even if the identification of cribriform pattern may have
interesting practical prognostic implications for oncologists
[1, 2]. In fact, it has been reported that CGC was associated
with higher stage, lymphovascular and perineural invasion
as well as with lower disease-free survival rate in comparison
to conventional histotypes of gastric carcinomas (GC) [3]. In
detail, the cribriform pattern has been reported in 9% of
unselected consecutively collected casuistry of gastric carci-
nomas (GC) with unfavourable prognostic outcome [3]. By
immunohistochemistry, neoplastic elements present in
CGC were diffusely stained with CK7 and CK19, but focally
for CK20 [3]. Moreover, MUC5AC has been also reported
as positive, while hormone receptors, CDX2, MUC1,
MUC2, and GCDFP-15, were always unexpressed [3].
Human epidermal growth factor receptor 2 (HER2) is
a 185 kDa transmembrane tyrosine kinase receptor, mem-
ber of the EGFR family, which plays a central role in
growth factor signal transduction [9]. HER2 overexpression/
amplification is involved in the development of various solid
tumors, playing a pivotal role in oncogenic tumorogenesis
and representing one of the most important therapeutic
target in oncology [10].
A phase III randomized study (ToGA) demonstrated a
significant survival benefit in patients affected by advanced
GC with HER2 overexpression and treated with combined
Hindawi
Disease Markers
Volume 2018, Article ID 1505428, 6 pages
https://doi.org/10.1155/2018/1505428
trastuzumab and chemotherapy, increasing the survival in
GC [9, 10]. In detail, it has been shown that the combination
of chemotherapy plus trastuzumab was statistically more
advantageous than chemotherapy alone, with an increased
median overall survival of nearly 3 months (OS 13.8 versus
11.1 months without trastuzumab), prolonging also the
progression-free survival and the response rate in GC
patients [9].
The rate of HER2 overexpression varies according to
the histotype of GC, with higher frequency evidenced in
the intestinal histotype (81.6%–91%) compared to the
diffuse or mixed (4%–7.9%). Of note, the pattern of HER2
immunoreactivity is frequently heterogeneous in intestinal
GC, which showed intermingled HER2-positive and HER2-
negative areas [11]. On the other hand, a more uniform
unreactive HER2 pattern was encountered in diffuse histo-
type [12, 13]. Although many authors have not clarified the
potential prognostic HER2 value, a larger number of studies
indicate that HER2 represents a negative prognostic factor,
showing more aggressive biological behavior and higher
frequency of recurrence in HER2-positive tumors [14–16].
In particular, it has been reported that HER2 overexpression
rate progressively increases moving from the poorly cohesive
WHO histotype to the mitochondrion-rich adenocarcinoma
(MRC), tubular adenocarcinoma, and hepatoid carcinoma
(HAS), which showed the highest frequency of HER2 pos-
itivity and the worst prognosis [12].
The aim of the present study is to firstly analyze the
HER2 status in a cohort of selected CGC in order to evaluate
the possible relationship with clinic-pathological characteris-
tics as well as prognostic parameters such as disease-free
interval and final outcome.
2. Materials and Methods
2.1. Patient Selection and Clinicopathologic Features. In the
period 2006–2015, one hundred ten surgically treated GC
with no neoadjuvant chemotherapy were selected from files
of our department of the University of Messina, Azienda
Ospedaliera Universitaria “Polyclinic G Martino” (Messina,
Italy). The enrollment was designed in order to have a larger
majority of intestinal type GC, in which the rate of CGC is
more frequent; in addition, the accessibility of follow-up data
has been considered a further element of choice.
The tumors were taken from an equal number of patients
(58 men and 52 women), mean age 68 years (range 40–84
years). A Gaussian distribution was used to calculate the
appropriate number of patients. 10 patients who died within
30 days after surgery (postoperative mortality) were excluded
from the study. Tumor localization in the stomach was lower
third in 57, middle third in 35, and upper third in 8 cases, five
of which were located at the gastrooesophageal junction. For
all cases, follow-up data were available, with a mean value
39.23 months (range 4–96 months), while the mean of
CGC patients was 34.24 months. The patients’ personal
details were nonidentifiable, and all the patients had provided
written consent to their medical information being used for
research purposes, according with the Helsinki declaration.
All gastric surgical specimens had been 10% neutral
formalin fixed for 24–48 hours and paraffin embedded at
56°C. Histotypes according to the WHO classification
revealed 49 tubular/papillary/mucinous adenocarcinomas,
24 poorly cohesive carcinomas, and 37 cases of CGC variant.
CGC variant was defined when at least 40% of the tumor
exhibited the occurrence of identifiable neoplastic glands
forming solid nests with round spaces (punch-out) leading
to a cribriform pattern, similarly to that elsewhere reported
[3]. This histological model greatly mimics the cribriform
pattern occurring in breasts or salivary glands. The patients
were staged using the seventh edition of the American Joint
Committee on Cancer Tumor Node Metastasis (TNM) stag-
ing system [12]. Clinicopathological data of 100 GC patients
were summarized in Table 1.
2.2. Immunohistochemical Procedures and Interpretation.
HER2 status has been evaluated by immunohistochemical
procedure on silane-coated slides carrying 3mm thick sec-
tions using HercepTest (DAKO). An antigen retrieval pre-
treatment was performed by three changes in 0.01M citrate
buffer pH6.0 in a microwave oven at 750W. Each immuno-
stained section was evaluated by the following score: 0
(absent staining); 1+ (faint and discontinuous membranous
staining in 10% of neoplastic elements); 2+ (light to moderate
lateral, basolateral, or complete membranous staining in 10%
of neoplastic elements); and 3+ (strong, intense lateral, baso-
lateral, or complete staining in 10% of neoplastic elements).
All cases considered equivocal (2+) have been furtherly
assessed by FISH test (pharmDx DAKO); nevertheless, as
the presence of some IHC1+/FISH amplified cases has been
reported elsewhere [10], 1+ cases were also submitted to
Table 1: Clinicopathological parameters in relation to HER2 status






Male 48 9 (18.8)
Female 52 12 (23.1)
Location NS
Upper third 8 1 (12.5)
Middle third 35 9 (25.7)
Lower third 57 11 (19.3)
Histological type NS
Cribriform 37 8 (21.6)
No cribriform 63 13 (20.6)
Stage 0.014
II 69 9 (13.0)
III 28 11 (39.3)
IV 3 1 (33.3)
Clinical course 0.009






the FISH procedure. Gene amplification was recorded when
the HER2 to CEP17 signal ratio was 2.0 or greater.
Statistical analysis was performed by chi-square test to
analyze associations between HER2 status and clinicopath-
ological parameters. Cancer-specific survival analysis was
performed by the Kaplan-Meier method, and for compar-
ison of the survival curves, the Mantel-Cox log-rank test
was used. A multivariate analysis (Cox regression model)
was utilized to determine the independent effects of variables
on overall survival. A p value less than 0.05 was considered
statistically significant. Data were analyzed using the SPSS
package V.6.1.3.
3. Results
Clinicopathological parameters as well as immunohisto-
chemical data in relation to HER2 status are summarized
in Table 1.
HER2 overexpression was encountered in 21 of 100
(21%) GC; in detail, 16 cases (16%) exhibited a 3+ score
and 5 of 12 cases with a 2+ score showed HER2 amplification
by the FISH test. Moreover, 66 cases exhibited 0 as the
HER2 score (66%), while six carcinomas (6%) were scored
as 1+, but none of these was amplified after the FISH
test. A progressive increase in HER2 overexpression was
appreciated moving from non-CGC (20.6%) towards CGC
cases (21.6) (Table 1).
Regarding tumor stage in relation to HER2 status, GC
were subdivided 69 in stage II (13% HER+), 28 stage III
(39.3% HER2+), and 3 stage IV (33.3% HER2+); the p value
was 0.014. Taking the clinical course into consideration,
29.5% of 61 patients died for GC showed HER2 expression/
amplification; only 7.7% showed HER2 overexpression in
39 alive patients; this difference was statistically significant
(p = 0 009) (Table 1).
When the analysis was limited to the CGC variant, the
overall HER2 amplification concerns 8 out 37 cases (21.6%);
in detail, 6/37 (16.22%) were scored as 3+ (Figure 1(a)), and
4/37 appeared equivocal with 2+ score, two of which showed
FISH amplification. Finally, 3/37 (8.10%) were 1+ and 24/37
(64.86%) were categorized as 0 (Figure 1(b)).
The survival curves of all patients as well as those of CGC
patients, with or without HER2 overexpression, performed
by the Kaplan-Meier method, were illustrated in (Figure 2).
In univariate analysis of all patients, stage (χ2 = 41 721)
and HER2 status (χ2 = 45 754) showed a significant p value
(<0.001); these two parameters maintained the same statis-
tical significance when only CGC patients were considered
(χ2 = 14 182) and (χ2 = 39 973), respectively (Table 2). By
multivariate survival analysis, the independent prognostic
(a) (b)
Figure 1: Cribriform gastric carcinoma (CGC): absence of HER2 immunoreactivity (a, original magnification ×160); a strong 3+ HER2
expression in another case (b, original magnification ×240) (Meier Haemalum nuclear counterstain).
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value of HER2 amplification was confirmed together with
the stage of GC (Table 3); moreover, similar results were
obtained taking into consideration only patients affected
by the CGC variant (Table 3).
4. Discussion
It is well known that HER2 overexpression in advanced
gastric carcinomas has been considered an independent
prognostic parameter, although its association with patient
survival or tumor metastatic status is still controversial
[10–13]. Moreover, a relationship between HER2 amplified
status and high grade, stage, Ki67 value and death for GC
has been previously elsewhere underlined [10–13]. In addi-
tion, it is noteworthy that the rate of HER2 overexpression
varies according to the GC histotype, with higher frequency
evidenced in intestinal histotype compared to the diffuse or
mixed one [17–20]. Interestingly, in a previous analysis
concerning unusual histotype of GC, we have already docu-
mented a progressive increase of HER2 amplification moving
from the poorly cohesive histotype to the mitochondrion-
rich adenocarcinoma, tubular adenocarcinoma, and hepatoid
carcinoma, which showed the highest frequency of HER2
positivity and the worse prognosis [12, 21]. Until now, no

















































Figure 2: Overall survival curves of all cases of gastric adenocarcinomas (a) and of the cribriform (CGC) variant (b) according to
HER2 status.
Table 2: Prognostic parameters examined in gastric carcinoma
cases: a univariate analysis of cancer-specific mortality by Mantel-
Cox log-rank test.
Variable X2 df p value
All patients (n = 100)
Sex 2.241 1 NS
Histological type 1.747 1 NS
Stage 41.721 1 0.000
HER2 status 45.754 1 0.000
CGC patients (n = 37)
Sex 0.219 1 NS
Stage 14.182 1 0.000
HER2 status 39.973 1 0.000
NS: not significant; df: degrees of freedom.
Table 3: Multivariate survival analysis by Cox regression model
gastric carcinoma cases.
Variable β SE Exp(β) p value
All patients (n = 100)
Stage 1.433 0.273 4.193 0.000
HER2 status 1.665 0.327 5.284 0.000
CGC patients (n = 37)
Stage 1.603 0.546 4.970 0.003
HER2 status 2.402 0.738 11.041 0.001
β: regression coefficient; SE: standard error: Exp(β): ratio of risk.
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adenocarcinomas with a prevalent cribriform pattern, a
morphological picture considered highly aggressive, able to
determine lymphovascular and perineural invasion as well
as a lower disease-free survival rate in comparison to
conventional GC [2, 3].
The strength of the present paper is to achieve, for
the first time, data regarding the potential prognostic
behavior of HER2 status in a selected unfrequent cohort
of CGC. Interestingly, the rate of HER2 amplification
slightly increased in the CGC group in comparison to
overall GC cohort (21.6% versus 20.6%), although, unfortu-
nately this difference does not reach a statistically significant
value. Nevertheless, the results might have been not enough
robust to show a statistically significant power as a conse-
quence of the low number of CGC cases; therefore, this latter
point should be considered as a limitation of the study and
requires a further validation in a larger CGC series. On the
other hand, a sporadic report concerning HER2 status in
CGC showed a 1+ score in 2/12 cases (16.6%) with no infor-
mation about the 2+ and 3+ scores [3]; consequently, these
literature data should be taken with caution due to a marked
bias in selection of CGC patients.
Survival curves of all analyzed GC patients showed that
patients with HER2 amplification had a shorter survival time.
This worse prognosis was further confirmed in the analysis of
CGC group in relation to HER2 status. Moreover, when CGC
were censored according HER2 overexpression in amplified
and unamplified cases, a significant prognostic HER2-
positive value emerged. This relevant prognostic feature
was greatly stressed, either in univariate or in multivariate
analysis, in which HER2 amplification appeared as one of
the main independent prognostic predictors of the cancer-
related deaths together with tumor stage. However, it has
been suggested that the occurrence of cribriform component,
independently of its percentage, is associated with decreased
overall survival and higher local recurrence, even if these data
are coming from a retrospective small study group, with a not
particularly prolonged follow-up period (29.7 months) [3].
Therefore, our data strongly support the peculiar behavior
of HER2 status in CGC after the present check in a larger
casuistry with a more extended follow-up time (34.24
months). Nevertheless, additional investigations are required,
to fully elucidate the biological reasons for the strong asso-
ciation between HER2 overexpression and CGC variant.
However, it has been reported that diffuse GC as well as
lobular breast carcinomas exhibited a reduced HER2 rate in
comparison to frequent mutations of E-cadherin, with an
inverse association [11, 22–24]; by contrast, in more than
50% of invasive cribriform breast carcinomas, a linear direct
association between HER2 positivity and E-cadherin immu-
noreactivity has been already documented [25]. Moreover, a
specific molecular signature for cribriform predominant
carcinomas, mainly of lung origin, has been considered dif-
ficult to be found [5], while it has revealed high rates of
KRAS and no EGFR mutations [26]. On this way, due to
the controversy over GC classification regarding cribriform
variant, supplementary studies are needed to verify a specific
association of molecular signature with HER2 amplification
in CGC patients.
5. Conclusions
Taking into practical evaluation the cribriform pattern as a
paradigmatic morphological adverse prognostic factor in
GC patients, also documented by its high HER2 overexpres-
sion rate, we invite all pathologists in their daily practice to
specify the occurrence of cribriform neoplastic component,
either in surgical or in bioptical samples, in order to correctly
treat these patients with worse behavior.
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